Investigational drug · Phase 2
PDC-1421
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Major Depressive Disorder.
Phase 2Last checked: Nov 20, 2026Latest source record: Apr 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "PDC-1421"
First trial start
2027
Jan 15, 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PDC-1421", any sponsor or status.
Conditions studied
As listed on its trial records.
- Major Depressive Disorder
Approved drugs for the same conditions: Depression (major depressive disorder) · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "PDC-1421" as an intervention, largest first.
BioLite, Inc.Industry
NCT05202327 · 99 participants · Start Apr 7, 2022 · Primary completion Dec 6, 2023
Drug: PDC-1421 Capsule; Placebo · For: Attention-Deficit Hyperactivity Disorder (ADHD)
Sites: San Francisco, California; Kaohsiung City, Taiwan; Taipei, Taiwan · 6 sites in all
BioLite, Inc.Industry
NCT02395978 · 72 participants · Start Apr 10, 2015 · Primary completion Mar 12, 2019
Drug: PDC-1421 Capsule; placebo · For: Major Depressive Disorder
Sites: San Francisco, California; Taipei, Taiwan; Taoyuan, Taiwan · 5 sites in all
BioLite, Inc.Industry
NCT01774045 · 30 participants · Start Nov 2012 · Primary completion Jul 2013
Drug: PDC-1421; Placebo · For: Major Depressive Disorder
Sites: Taipei, Taiwan
BioLite, Inc.Industry
NCT03833206 · 12 participants (planned) · Start Jan 15, 2027 · Primary completion Feb 28, 2028
Drug: PDC-1421 Capsule · For: Major Depressive Disorder
Sites: Los Angeles, California
- A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)Completed
BioLite, Inc.Industry
NCT02699086 · 6 participants · Start Dec 1, 2019 · Primary completion Jul 15, 2020
Drug: PDC-1421 Capsule · For: Attention-Deficit Hyperactivity Disorder (ADHD)
Sites: San Francisco, California
Newest research
PubMed records naming it or its code names, newest first.
- The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium.
Ilipilla G, Arnold LE · Expert Opin Pharmacother 2024
Also in development for Major Depressive Disorder
- BrenipatideLY3537031Phase 313 trials
Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major
- AzetukalnerXEN1101Phase 39 trials
Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- BHV-7000Phase 36 trials
Biohaven Therapeutics Ltd. · Focal Epilepsy, Major Depressive Disorder, Bipolar Disorder
- NBI-1065845TAK-653, OsavampatorPhase 35 trials
Neurocrine Biosciences · Major Depressive Disorder
- CYM-53093Navacaprant, NMRA-335140Phase 34 trials
Neumora Therapeutics, Inc. · Major Depressive Disorder, Major Depressive Episode Associated With Bipolar II Disorder
- DT120MM120, lysergide tartratePhase 34 trials
Definium Therapeutics US, Inc. · Generalized Anxiety Disorder, Major Depressive Disorder
- PsilocybinCOMP360Phase 34 trials
COMPASS Pathways · Treatment Resistant Depression, Major Depressive Disorder, Anorexia Nervosa
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.